
CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention
Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.
CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is to assess if the antibody can prevent HIV infection in humans as effectively as it does in monkeys. If shown to be effective in preventing HIV, the antibody, in conjunction with the VRC’s VRC07 antibody, has the potential to break the HIV infection cycle. However, the difficulties in manufacturing the antibody have been an obstacle in the research and development of CAP256. These obstacles can be overcome and the production of this antibody can be markedly improved.
Mediated by kENUP Foundation, Evotec SE intends to enter into a long-term collaboration with CAPRISA to further optimize and develop CAP256, using innovative approaches they have developed and used successfully with other antibodies. The collaboration will leverage the capabilities at Just – Evotec Biologics in optimizing manufacturing processes through artificial intelligence and machine learning. The result is a more productive manufacturing process for lower cost and wider access for the product. Evotec’s centers of excellence in Redmond (US) and Toulouse (France) will play a key role for enhancing the antibody’s production, facilitating co-formulation of the CAP256-VRC07 combination and manufacturing CAP256 for clinical trials. CAPRISA is conducting clinical trials of these antibodies in conjunction with the Center for Infectious Diseases Research in Zambia, with the support of the European Union – Developing Countries Clinical Trial Partnership.
In the presence of Hon. Dr Daniel Ngamije, Minister of Health of the Republic of Rwanda, Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa, and Antoine Anfré, French Ambassador to the Republic of Rwanda, the participants of the AU-EU Ministerial Meeting discussed the project’s potential impact on resilience and independence of African health systems.
Prof Salim Abdool Karim, Director of CAPRISA: “We are excited to work with Evotec and the VRC in this project to improve the CAP256 manufacturing processes. It is the culmination of a decade of research to develop CAP256 in order to assess whether this antibody, which originated in Africa, is effective for preventing HIV in Africa.”
Dr Werner Lanthaler, Chief Executive Officer of Evotec SE: “We look forward to collaborate on re-engineering CAP256. We will use and build global capacities to maximize impact for this important product. This is core of our mission to maximize access to modern biologics also in Africa.”
Hon. Dr Daniel Ngamije, Minister of Health, Republic of Rwanda: “Rwanda is focused on creating a biopharmaceutical ecosystem. With the work of CAPRISA and Evotec on monoclonal antibodies, we have the potential to finally ensure Africa’s access to highly effective therapeutics for many diseases endemic to our continent. This effort has Rwanda’s full support.”
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
About CAPRISA
CAPRISA is a world-leading AIDS research centre based in Africa. It is renowned for its research that showed that high rates of HIV in Africa are driven by “The Cycle of HIV Transmission” where young women partner with men about 10 years older. CAPRISA provided the first evidence that topical antiretrovirals prevent HIV infection. It has since been leading the development of several new HIV prevention technologies in Africa. The five major partner institutions that constitute CAPRISA are: University of KwaZulu-Natal, University of Cape Town, University of the Western Cape, National Institute for Communicable Diseases and Columbia University in New York. CAPRISA has diverse expertise in basic and molecular epidemiology, virology, immunology, infectious disease medicine, bioinformatics, statistics, ethics and health policy. CAPRISA is headquartered at the Nelson R Mandela Medical School at the University of KwaZulu-Natal in Durban, South Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005445/en/
Contact information
Press contact
Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing,
Phone: +49.(0)40.56081-255
gabriele.hansen@evotec.com
Hinnerk Rohwedder, Senior Specialist Corporate Communications
Phone: +49.(0)40.56081-281
hinnerk.rohwedder@evotec.com
CAPRISA:
Smita Maharaj, Head of Communications, CAPRISA
Phone: +27 82 806 9931
smita.maharaj@caprisa.org
kENUP:
Julia Kärger
Phone: +356 7986 0105
kaerger@kenup.eu
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo